Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis

Recruiting

Phase 3

Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis

Sponsor:

Alumis Inc

Code:

NCT06846541

Conditions

Plaque Psoriasis

Psoriasis (PsO)

Psoriasis

Moderate Psoriasis

Severe Psoriasis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Open-Label ESK-001

Blinded ESK-001

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-16. This information was provided to ClinicalTrials.gov by Alumis Inc on 2025-05-28.